HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

FDA chief’s exit clouds already murky drug approvals

During Dr. Martin Makary’s tenure as commissioner, the FDA faced pushback over high-profile drug rejections for Replimune and UniQure.

By PharmaVoice · May 14, 2026 · via PharmaVoice
FDA chief’s exit clouds already murky drug approvals

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
policyformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
US taps small San Diego biotech for experimental Ebola treatment as epidemic worsens
PolicyFierceBiotech ↗
US taps small San Diego biotech for experimental Ebola treatment as epidemic worsens
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-know…
May 25, 2026
Lilly Targets Church-Linked Pharmacies in $200M Trulicity Rebate Fraud Allegation
PolicyBriefing
Lilly Targets Church-Linked Pharmacies in $200M Trulicity Rebate Fraud Allegation
Eli Lilly’s lawsuit claims church-affiliated pharmacies and wholesalers defrauded it through fake rebate claim…
May 25, 2026
STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further
PolicySTAT News ↗
STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further
The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable sh…
May 22, 2026